Formulation and Evaluation of Solid Lipid Nanoparticles of Olanzapine for the Treatment of Psychosis
Solid lipid nanoparticles (SLN) are typically spherical with an average diameter between 1 nm to 1000 nm in range. It is alternative carrier systems to tradition colloidal carriers, such as liposomes emulsions and polymeric micro and nanoparticles. Olanzapine (OZP) is an atypical antipsychotic agent which is used for treatment of Schizophrenia. Its oral bioavailability is around of 40%. OZP is a class II drug so it having low aqueous solubility. To overcome that problem and to increase its bioavailability, the solid lipid nanoparticles of olanzapine are prepared. Formulation batches designed by modifying type of surfactant ( Span 80, Tween 80), concentration of surfactant, Concentration of co-surfactant, type of lipid ( glyceryl monostearate, Stearic acid), Lipid concentration, speed of stirring and time of stirring using customised design of DOE. The SLN were prepared by high speed homogenization technique, and then characterized by particle size analysis, Drug entrapment efficiency and Drug diffusion study. A formulation containing GMS as a lipid stabilised with tween 80 as surfactant show good drug release, smaller particle size, as compared with other formulations with different lipid and surfactant. The present research findings indicate that OZP loaded solid lipid Nano particulate system for delivery of OZP with better efficacy with minimum adverse effects.
Keywords: Olanzapine, SLN, GMS, high speed homogenization and DOE.
2. Ekambaram P, Sathali H, A. Abdul, Formulation and Evaluation of Solid lipid nanoparticles of Ramipril, Journal of Young pharmacists, 2011; 3(3):216-220.
3. Joseph E, Reddi S, Rinwa V, Balwani G, Saha R, Design and in vivo evaluation of solid lipid nanoparticulate systems of Olanzapine for acute phase schizophreniea treatment: Investigations on antipsychotic potential and adverse effects, European Journal of Pharmaceutical Sciences, 2017; 1(1):1-29.
4. Vivek K, Reddy H, Murthy RSR, “Investigations of the Effect of the Lipid Matrix on Drug Entrapment, In Vitro Release, and Physical Stability of Olanzapine-Loaded Solid Lipid Nanoparticles” AAPS PharmSciTech 2007; 8 (4):1-9.
5. Das AK, Bhanja S, Swetha T, Priyadarshini B, “Formulation and in-vitro evaluation of Olanzapine tablet for Schizophrenia and Bipolar disorder” International Journal of Pharmaceutical sciences and Research, 2014;5(1):148-155.
6. Prasanna Kumar PSS, Vijaya Kumar G, Sravani B, “Design, Formulation and In vitro evaluation of Olanzapine matrix sustained release tablets using natural polymers” World journal of Pharmacy and Pharmaceutical Science, 2017; 6(6):1442-1459.
7. Maheswarappa MK, Desai PD, “Design and in-vitro evaluation of mouth dissolving tablets of olanzapine” Asian Journal of Pharmaceutics, 2011; 5(1):107-113.
8. Gupta VN, Gowda DV, Balamuralidhara V, Mohammed Khan S, “Formulation and evaluation of olanzapine matrix pellets for controlled release” DARU, 2011; 19(4):249-256.
9. Patel RB, Patel MR, Bhatt KK, Patel BJ, Formulation and Evaluation of Microemulsions- Based drug delivery system for intranasal administration of Olanzapine, International Journal of Biomedical and Pharmaceutical Sciences, 2013; 7 (1):20-27.
10. Pandey VP, Joysa Ruby J, Formulation and evaluation of olanzapine loaded chitosan nanoparticles for nose to brain targeting an in vitro and ex vivo toxicity study, Journal of Applied Pharmaceutical Science, 2016; 6(9):034-040.
11. Sawant KK, Seju U, Kumar A, Development and Evaluation of Olanzapine loaded PLGA nanoparticles for nose to brain delivery: In vitro and In Vivo studies, Acta Biomaterialia, 2011; 7:4169-4176.
12. Kumar M, MIishra A, Mishra AK, Mishra P, Pathak K, Mucoadhesive nanoemulsion-based intranasal drug delivery system of olanzapine for brain targeting, Journal of Drug Targeting, December 2008; 16(10):806–814.
13. Abdelbary GA, Tadros MI, “Brain targeting of olanzapine via intranasal delivery of core - shell difunctional block copolymer mixed nanomicellar carriers: in-vitro characterization, ex-vivo estimation of nasal toxicity and in-vivo biodistribution studies” International Journal of Pharmaceutics, 2013; 1(1):1-51.
14. Farzaneh S, Lish SB, Abdouss M, Asadi E, Azodi-Deilami S, Khonakdar SA, Gharghabi M, Molecularly imprinted polymer nanoparticles for olanzapine recognition: application to solid phase extraction and sustained release” Royal society of chemistry advances, 2014; 1(1):1-46.
15. Vauthier C. Polymer Nanoparticles for In Vivo Applications: Progress on Preparation Methods and Future Challenges, Springer International Publishing Switzerland, 2016; 1:1-16.
16. Iqbala N, Vitorinob C, Taylora KMG. How can lipid nanocarriers improve transdermal delivery of olanzapine, Pharmaceutical Development and Technology, 2016; 1:1-11.
17. Shailaja M, Diwan PV, Ramakrishna Ramesh SG, Reddy KH, Rao YM. Development of Olanzapine Nano-Emulsion for Enhanced Brain Delivery, International Journal of Pharmaceutical Sciences and Nanotechnology, 2012; 5(1):1648-1659.
18. Natarajan J, Baskaran M, Humtose LC, Vadivelan R, Justin A. Enhanced brain targeting efficacy of olanzapine through solid lipid nanoparticles, Journal of artificial cells, nanomedicine, and biotechnology, 2017; 45(2):1-23.
19. Ekambaram P, Abdul Hasan Sathali A, Priyanka K. A review of Solid Lipid Nanoparticles, Journal of Scientific Reviews and Chemical Communications, 2012; 2(1):80-102.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).